Bristol Myers Squibb And 2seventy Bio Announce Topline Results From KarMMa-3 Trial Showing AbecmaLeading Pharmaceutic… · 11:53 15 Aug 2022Bristol Myers Squibb and 2seventy bio, Inc.announced positive topline results from KarMMa-3, a Phase 3, global, randomized, multicenter, open-label study evaluating Abecma (idecabtagene vicl… Read More